- Cannabis fintech marketplace innovator MAZAKALI is helping investors and issuers navigate the hurdles of an industry experiencing renewed vitality
- A supportive presidential administration along with continued state-level legalization is serving as a boon to cannabis market interests
- Professional sports leagues have become increasingly friendly to player use, reducing or eliminating cannabis-related drug testing protocols and punishments
- Market analysts forecast global revenues of $358.8 billion by 2027, an annual growth rate of 14.3% percent over 2020’s valuation. In the United States, the industry is growing at nearly twice that rate – boasting a projected annual growth of 27% over the next five years
Cannabis marketplace facilitator MAZAKALI is anticipating a bumper year for governmental and private industry policy-making regarding the leafy green plant’s product potential. Now legal under medical supervision in 35 U.S. states and permitted for adult use in 15 states, cannabis is poised to become the best performing asset class of the decade, according to a market forecast published recently by MAZAKALI.
The report, titled “Cannabis 2021: Five Things to Watch,” outlines expectations for the rise of cannabis-infused beverages in the United States, improved production of rare cannabinoids through biosynthesis, growing capital infusion, accelerating acceptance under state and local laws, and increasing openness to cannabis’ psychoactive products by world governments on a national scale (https://ibn.fm/P6UlZ).
“We’re seeing a huge increase of products in the health and wellness sector and I think we’ll see more women designing cannabis products for women,” infused drinks-maker K-Zen’s CEO, Judy Yee, told Forbes in a recent report (https://ibn.fm/lZIQh).
“Women will be a big force in normalizing cannabis,” she predicted.
The report also notes that while the NBA is now the only major sports league that suspends players from games for cannabis use, it has also temporarily stopped testing players for the plant amid the pandemic (https://ibn.fm/v47h6). The company applauded the United Nations’ decision in December to accept a recommendation by the World Health Organization to delist cannabis from its most restrictive Schedule IV classification under international drug control treaties. Its use for non-medical and non-scientific purposes remains in that classification (https://ibn.fm/K2ZuW).
The global cannabis market is expected to grow from $140.7 billion in 2020 to $358.8 billion in 2027 at a CAGR of 14.3 percent, according to the most recent Grand View Research analysis (https://ibn.fm/G0Dc9).
MAZAKALI uses GreenPapers(R) such as its “Cannabis 2021” report to inform the public about cannabis markets because it believes in the concept of “Authority Through Knowledge” when it comes to helping a company maneuver through the hurdles modern-day market regulations can present on the path to profitability.
The company is based in San Francisco and has been supporting cannabis businesses in raising capital and investors in placing capital since 2016.
MAZAKALI’s experienced and licensed professionals deliver services to investors that include an online investment marketplace to handle direct investments in a diverse field of vetted opportunities, personalized portfolio management for highly funded clients, and an Outsourced Cannabis Investment Officer (“OCIO”) service to institutions seeking advice on their cannabis portfolio allocation practices.
MAZAKALI’s services to issuers include direction through the capital-raising process on a stage-by-stage basis, following them from early preparations through offering structure, modeling, pitch preparation and launch. The company’s intuitive digital interface enables companies to pursue their ambitions with ease and confidence.
For more information, visit the company’s website at www.MAZAKALI.com.
NOTE TO INVESTORS: The latest news and updates relating to MAZAKALI are available in the company’s newsroom at https://ibn.fm/MAZAKALI